https://doi.org/10.4081/monaldi.2021.1867
Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma
Submitted: March 27, 2021
Accepted: May 12, 2021
Published: June 10, 2021
Accepted: May 12, 2021
Abstract Views: 1704
PDF: 769
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Covid-19 in immunocompromised patients shows a prolonged course and may lead to a poor prognosis. Although data on hyperimmune plasma for treatment of Covid-19 suggest an improved outcome in immunocompetent patients, limited data are currently available in immunocompromised patients. We present the case of a 62-year-old Caucasian woman, who was previously treated with obinutuzumab and bendamustine for follicular lymphoma and showed a prolonged positive test for Covid-19. Since no improvement was observed with standard of care (including remdesivir), the possibility of hyperimmune plasma infusion was discussed. A first dose of hyperimmune plasma was administered, with subsequent onset of fever, increasing inflammatory indexes and worsening radiological findings. Three days later a second dose of plasma was administered. Within twelve hours cough and fever disappeared, and oxygen at rest was discontinued. The patient was discharged 5 days later, and nasopharyngeal swabs resulted negative 16 days after discharge.
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-3.
DOI: https://doi.org/10.1056/NEJMoa2001017
Karataş A, İnkaya AÇ, Demiroğlu H, et al. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. Transfus Apher Sci 2020;59:102871.
DOI: https://doi.org/10.1016/j.transci.2020.102871
Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov 2020;10:783-91.
DOI: https://doi.org/10.1158/2159-8290.CD-20-0422
Malsy J, Veletzky L, Heide J, et al. Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19. Clin Infect Dis 2020:ciaa1637. Online ahead of print.
DOI: https://doi.org/10.1093/cid/ciaa1637
Ferrari S, Caprioli C, Weber A, et al. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leuk Lymphoma 2021;62:1490-6.
DOI: https://doi.org/10.1080/10428194.2021.1872070
Shah V, Ko Ko T, Zuckerman M, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with hematological malignancies; King’s College Hospital experience. Br J Haematol 2020;190:e279-282.
DOI: https://doi.org/10.1111/bjh.16935
Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 2020;383:2291-3.
DOI: https://doi.org/10.1056/NEJMc2031364
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - Final Report. N Engl J Med 2020;383:1813-26.
DOI: https://doi.org/10.1056/NEJMc2022236
Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020;117:9490–6.
DOI: https://doi.org/10.1073/pnas.2006961117
Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582-9.
DOI: https://doi.org/10.1001/jama.2020.4783
Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med 2021;384:610-8.
DOI: https://doi.org/10.1056/NEJMoa2033700
Wright Z, Bersabe A, Eden R, et al. Successful use of COVID-19 convalescent plasma in a patient recently treated for follicular lymphoma. Clin Lymphoma Myeloma Leuk 2021;21:66-8.
DOI: https://doi.org/10.1016/j.clml.2020.06.012
Supporting Agencies
NoneHow to Cite
Levi, Guido, Chiara Rocchetti, Roberto Magri, Silvia Uccelli, Damiano Bottone, Federico Quadri, Mauro Novali, Alessandro D. Santin, and Michela Bezzi. 2021. “Hyperimmune Plasma Infusion in an Immunocompromised Covid-19 Patient Previously Treated for Follicular Lymphoma”. Monaldi Archives for Chest Disease 91 (4). https://doi.org/10.4081/monaldi.2021.1867.
Copyright (c) 2021 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Eduardo Bossone, Ciro Mauro, Alfonso Maiellaro, Eliana Raiola, Rosangela Cocchia, Brigida Ranieri, Chiara Sepe, Valentina Capone, Salvatore Chianese, Renato Maramaldi, Enrico Pasquale Acerra, Gaetano Mirto, Sergio Lodato, Giuseppe Russo, Giuseppe Longo, Cardiac teleconsulting in the time of COVID-19 global pandemic: The “Antonio Cardarelli” Hospital project , Monaldi Archives for Chest Disease: Vol. 91 No. 2 (2021)
- Laxmi Pattanashetti, Santosh Patil, Sanath Nyamgouda, Mahendrakumar Bhagiratha, Pramod Gadad , COVID-19 and pregnant women – An overview on diagnosis, treatment approach with limitation, and clinical management , Monaldi Archives for Chest Disease: Vol. 91 No. 3 (2021)
- Marco Moscarelli, Ruggero De Paulis, The phyllotaxis of the aortic valve , Monaldi Archives for Chest Disease: Vol. 89 No. 3 (2019)
- Nitesh Gupta, A J Mahendran, Shibdas Chakrabarti, Sumita Agrawal, Microscopic polyangiitis in a case of silica exposure: a rare presentation , Monaldi Archives for Chest Disease: Vol. 89 No. 3 (2019)
- Yamini Marimuthu, Radhika Kunnavil, NS Anil, Sharath Burugina Nagaraja, N Satyanarayana, Jeetendra Kumar, Bojja Ramya, Clinical profile and risk factors for mortality among COVID-19 inpatients at a tertiary care centre in Bengaluru, India , Monaldi Archives for Chest Disease: Vol. 91 No. 3 (2021)
- Pratap Upadhya, Rohit Vadala, Arpitha A, Hospital treatment of severe acute exacerbation of chronic obstructive pulmonary disease in COVID-19 situation: back to basics , Monaldi Archives for Chest Disease: Vol. 90 No. 4 (2020)
- Ramakant Dixit, Mukesh Goyal, Paras Nowal, Varna Indushekhar, Adenocarcinoma lung presenting with meningeal carcinomatosis , Monaldi Archives for Chest Disease: Vol. 92 No. 2 (2022)
- Parul Mrigpuri, Sonal Sonal, Sonam Spalgais, Nitin Goel, Balakrishnan Menon, Raj Kumar, Uncontrolled diabetes mellitus: A risk factor for post COVID fibrosis , Monaldi Archives for Chest Disease: Vol. 91 No. 1 (2021)
- Nitin Goel, Nitesh Goyal, Raj Kumar, Exertional dyspnea and hemoptysis in an adolescent: is it tuberculosis only? , Monaldi Archives for Chest Disease: Vol. 91 No. 1 (2021)
- Ignasi Garcia-Olivé, Helena Sintes, Joaquim Radua, Jordi Deportos, Isabel Nogueira, Cristian Morales-Indiano, Jorge Abad Capa, Antoni Rosell, Predicting pulmonary embolism in patients infected with COVID-19 based on D-dimer levels and days between diagnosis of the infection and D-dimer determination , Monaldi Archives for Chest Disease: Vol. 91 No. 2 (2021)
<< < 44 45 46 47 48 49 50 51 52 53 > >>
You may also start an advanced similarity search for this article.
